Incannex Healthcare (IXHL) Expected to Announce Earnings on Thursday

Key Points

• Incannex Healthcare is expected to report Q3 2026 results on May 14, with analysts forecasting EPS of ($0.60) and revenue of $0.20M, and an earnings call set for May 15 at 9:30 AM ET.
• The stock opened at $4.91 with a market cap of $58.6M and a 1‑year range of $2.40–$49.80, and analysts have an average rating of "Sell".
• Incannex is a clinical‑stage biopharma developing cannabinoid and psychedelic therapies; several hedge funds have recently increased positions but institutional ownership remains low (~0.43%).

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) is projected to release its Q3 2026 resultson Thursday, May 14th. Analysts expect Incannex Healthcare to post earnings of ($0.60) per share and revenue of $0.20 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) last released its quarterly earnings results on Friday, February 13th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). On average, analysts expect Incannex Healthcare to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Incannex Healthcare Price Performance

NASDAQ IXHL opened at $4.91 on Thursday. The stock has a market capitalization of $58.59 million, a PE ratio of -0.58 and a beta of 7.22. The business has a 50 day simple moving average of $3.74 and a two-hundred day simple moving average of $8.25. Incannex Healthcare has a 1-year low of $2.40 and a 1-year high of $49.80.

Hedge Funds Weigh In On Incannex Healthcare

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC boosted its holdings in Incannex Healthcare by 87.3% during the 4th quarter. Virtu Financial LLC now owns 753,675 shares of the company's stock valued at $270,000 after acquiring an additional 351,232 shares during the period. Arete Wealth Advisors LLC boosted its holdings in Incannex Healthcare by 88.7% during the 4th quarter. Arete Wealth Advisors LLC now owns 2,223,450 shares of the company's stock valued at $796,000 after acquiring an additional 1,044,862 shares during the period. Jane Street Group LLC boosted its holdings in Incannex Healthcare by 547.4% during the 4th quarter. Jane Street Group LLC now owns 1,491,835 shares of the company's stock valued at $534,000 after acquiring an additional 1,261,385 shares during the period. Finally, LPL Financial LLC boosted its holdings in Incannex Healthcare by 639.1% during the 4th quarter. LPL Financial LLC now owns 335,373 shares of the company's stock valued at $120,000 after acquiring an additional 290,000 shares during the period. Hedge funds and other institutional investors own 0.43% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on IXHL. Weiss Ratings restated a "sell (e+)" rating on shares of Incannex Healthcare in a report on Tuesday, April 21st. Wall Street Zen cut Incannex Healthcare from a "hold" rating to a "sell" rating in a report on Monday, March 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Incannex Healthcare has an average rating of "Sell".

About Incannex Healthcare

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company's research and development pipeline includes multiple product candidates in various stages of clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.